Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q1 '18: 2.1M Q2 '18: 2.6M Q3 '18: 2.9M Q4 '18: 4.8M Q1 '19: 5.8M Q2 '19: 34M Q3 '19: 35.5M Q4 '19: 36.1M Q1 '20: 36M Q2 '20: 7.2M Q3 '20: 5.9M Q4 '20: 3.9M Q1 '21: 2.8M Q2 '21: 2.7M Q3 '21: 1.5M Q4 '21: 881.7K Q1 '22: 233.9K Q2 '22: 97.3K Q3 '22: 0 Q4 '22: 0 Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -66.8M Q4 '21: -56M Q1 '22: -49.1M Q2 '22: -44.7M Q3 '22: -39M Q4 '22: -39.8M Q1 '23: -48.6M Q2 '23: -44.5M Q3 '23: -45.8M Q4 '23: -45.1M Q1 '24: -37.4M Q2 '24: -40.2M Q3 '24: -46.2M Q4 '24: -48.7M Q1 '25: -58.9M Q2 '25: -67M Q3 '25: -75.9M Q4 '25: -85.3M Q1 '26: -89.8M Q2 '26: -106.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -44M Q4 '21: -45.6M Q1 '22: -39M Q2 '22: -35.1M Q3 '22: -41.7M Q4 '22: -42.3M Q1 '23: -50.7M Q2 '23: -46.2M Q3 '23: -47.5M Q4 '23: -44.6M Q1 '24: -33.8M Q2 '24: -35M Q3 '24: -38.7M Q4 '24: -40.2M Q1 '25: -50.3M Q2 '25: -58M Q3 '25: -67.5M Q4 '25: -78.5M Q1 '26: -84.5M Q2 '26: -101.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -56.7M Q4 '21: -48.2M Q1 '22: -37M Q2 '22: -31.7M Q3 '22: -39.8M Q4 '22: -37.5M Q1 '23: -42M Q2 '23: -37.6M Q3 '23: -37.5M Q4 '23: -36.1M Q1 '24: -29M Q2 '24: -30.1M Q3 '24: -36.9M Q4 '24: -41.8M Q1 '25: -50.2M Q2 '25: -57.9M Q3 '25: -59.5M Q4 '25: -64.5M Q1 '26: -73.6M Q2 '26: -86.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q2 '17: -21.1M Q3 '17: -24.4M Q4 '17: -28.5M Q1 '18: -24.7M Q2 '18: -25.2M Q3 '18: -27.7M Q4 '18: -32.4M Q1 '19: -19.3M Q2 '19: -29.6M Q3 '19: -38.9M Q4 '19: -48.5M Q1 '20: -86.8M Q2 '20: -96.8M Q3 '20: -105.9M Q3 '22: -39.9M Q4 '22: -37.6M Q1 '23: -42M Q2 '23: -37.6M Q3 '23: -37.5M Q4 '23: -36.1M Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q1 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '19: 68.5M Q2 '20: 73.9M Q3 '20: 81.9M Q1 '21: 116.3M Q2 '21: 116.4M Q3 '21: 125.2M Q1 '22: 4.2M Q2 '22: 4.2M Q3 '22: 4.2M Q1 '23: 4.2M Q2 '23: 4.3M Q3 '23: 4.4M Q1 '24: 8.3M Q2 '24: 11.1M Q3 '24: 12M Q1 '25: 12.2M Q2 '25: 12.2M Q3 '25: 12.3M Q1 '26: 18.7M Q2 '26: 19.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '21: -0.36 Q4 '21: -11.17 Q1 '22: -13.29 Q2 '22: -16.32 Q3 '22: -18.41 Q4 '22: -10.15 Q1 '23: -12.13 Q2 '23: -11.00 Q3 '23: -11.16 Q4 '23: -10.35 Q1 '24: -6.94 Q2 '24: -5.79 Q3 '24: -4.67 Q4 '24: -3.64 Q1 '25: -4.20 Q2 '25: -4.74 Q3 '25: -5.49 Q4 '25: -5.90 Q1 '26: -5.74 Q2 '26: -6.11 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.